![5-carboxyRh110-SUMO-Dha-0 5-carboxyRh110-SUMO-Dha-0](https://ubiqbio.com/wp-content/uploads/2016/08/figure_i_fact_sheet_farid_version_2_1_2_2-600x213.png)
cRh110-SUMO2-Dha
an activity-based probe for the SUMO ligation pathway, labeled with 5-carboxyrhodamine110 on the N-terminus
Additional information
Weight | 0.005 kg |
---|---|
aliquot size | |
Applications | Crystallization, Pull down, Purification, Western Blot, Phenotypic protein profiling, Target inhibitor profiling |
target | |
source | |
shipping | |
purity | |
molecular weight | |
storage | Powder at −20°C; solution at −80°C. Protect from light. Please avoid multiple freeze/thaw cycles. |
sample preparation | For detailed sample preparation see product sheet. |
regulatory statement |
€350.00
- Description
- Additional information
Description
UbiQ-143 (cRh110-SUMO2-Dha) is a fluorescent activity-based probe for SUMO E1, E2 and (HECT/RBR) E3 ligases. It is based on the SUMO2 sequence in which the C-terminal Gly has been replaced by a dehydroalanine (Dha) residue and Cys48 by a Ser residue. The N-terminus is labeled with a 5-carboxyrhodamine110 dye (cRh110, λex= 480 nm; λem= 520 nm) allowing for a sensitive and fast detection.
UbiQ-143 is processed in a native manner by SUMO E1, E2 and E3 enzymes and during this process it forms an electrophilic intermediate that can react with the active site Cys residue, thereby creating a covalent bond.
Mulder et al., A cascading activity-based probe sequentially targets E1–E2–E3 ubiquitin enzymes. Nature Chem Biol (2016) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108872/
Additional information
Weight | 0.005 kg |
---|---|
aliquot size | |
Applications | Crystallization, Pull down, Purification, Western Blot, Phenotypic protein profiling, Target inhibitor profiling |
target | |
source | |
shipping | |
purity | |
molecular weight | |
storage | Powder at −20°C; solution at −80°C. Protect from light. Please avoid multiple freeze/thaw cycles. |
sample preparation | For detailed sample preparation see product sheet. |
regulatory statement |